Literature DB >> 22118843

Comparison of fat-free mass in super obesity (BMI ≥ 50 kg/m2) and morbid obesity (BMI <50 kg/m2) in response to different weight loss surgeries.

Gladys W Strain1, Michel Gagner, Alfons Pomp, Gregory Dakin, William B Inabnet, Taha Saif.   

Abstract

BACKGROUND: Differences in excess weight loss, body mass index (BMI) change, and body composition have been related to different types of bariatric procedures. Our objective was to explore these alterations related to body mass in superobese (SO) and morbidly obese (MO) patients in a university hospital setting.
METHODS: Patients provided written informed consent and had their body composition measured before and after surgery using bioimpedance (Tanita 310). The t test was used to compare MO and SO. Pearson's correlations were used to examine the BMI, excessive BMI loss, percentage of body fat (BF) change, and fat-free mass.
RESULTS: A total of 133 MO patients had a BMI of 43.3 kg/m(2) and 88 SO patients had a BMI of 59.4 kg/m(2). The percentage of BF was 46.7% and 51.9% (P < .0001). The differences in the follow-up period after surgery (21.5 and 20.6 months; P = .62) and patient age (43.4 and 42.5 yr) were not significant, but the gender distribution was significant (P = .003). After surgery, the MO patients had a BMI of 30.9 ± 5.7 kg/m(2) and the SO patients had a BMI of 37.3 ± 9.0 kg/m(2). The percentage of BF was not different between the 2 groups (MO, 33.1% ± 9.6% and SO, 35.0% ± 12.4%; P = .21). Gender differences in the percentage of BF were present before surgery; however, after surgery, these were absent for the men in the 2 groups (24.8% and 26.6%; P = .51). The change in the BMI and the change in the BF had a stronger correlation for the MO patients (r = .83 versus r = .53) than for the SO patients. The fat-free mass loss correlated with the change in BMI without regard to procedure. The percentage of excessive BMI loss was 65.1% for the MO and 63.4% for the SO patients (P = .64).
CONCLUSIONS: The SO patients achieved excessive BMI loss similar to that of the MO patients, with more SO men choosing biliopancreatic diversion/duodenal switch. At a BMI of 37.3 kg/m(2), the SO patients had a percentage of BF that was not different from that of the MO patients at 30.9 kg/m(2). The fat-free mass losses correlated with the change in BMI.
Copyright © 2012 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22118843     DOI: 10.1016/j.soard.2011.09.028

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

1.  Endpoint of Bariatric Surgery is Not Only Preservation of Free Fat Mass but Restoration of Normal Body Composition.

Authors:  Luigi Angrisani; Antonio Vitiello; Ariola Hasani; Antonella Santonicola; Patrizia Colicchio
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

Review 2.  Practical Considerations for Body Composition Assessment of Adults with Class II/III Obesity Using Bioelectrical Impedance Analysis or Dual-Energy X-Ray Absorptiometry.

Authors:  Carlene A Johnson Stoklossa; Mary Forhan; Raj S Padwal; Maria Cristina Gonzalez; Carla M Prado
Journal:  Curr Obes Rep       Date:  2016-12

3.  Validity of bioelectrical impedance analysis for measuring changes in body water and percent fat after bariatric surgery.

Authors:  Elizabeth M Widen; Gladys Strain; Wendy C King; Wenwen Yu; Susan Lin; Bret Goodpaster; John Thornton; Anita Courcoulas; Alfons Pomp; Dympna Gallagher
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

4.  Effect on Nitrogen Balance, Thermogenesis, Body Composition, Satiety, and Circulating Branched Chain Amino Acid Levels up to One Year after Surgery: Protocol of a Randomized Controlled Trial on Dietary Protein During Surgical Weight Loss.

Authors:  Violeta Moizé; Xavier Pi-Sunyer; Josep Vidal; Patricia Miner; Yves Boirie; Blandine Laferrère
Journal:  JMIR Res Protoc       Date:  2016-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.